Triptolide, derived from the traditional Chinese herb, Tripterygium wilfordii, sensitizes cancer cells to apoptosis. Glioblastoma multiforme (GBM), which accounts for most cases of central nervous malignancy, has a very poor prognosis and lacks effective therapeutic inventions. We, therefore, investigated the effects of different concentrations of, and different periods of exposure to, triptolide on cell proliferation and apoptosis in the glioma cell lines, U251MG and U87MG, and in normal human fetal astrocytes. Cell proliferation was investigated by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay and growth curve analysis, and apoptosis was assessed from genomic DNA fragmentation. Triptolide showed dose-dependent inhibition of cell proliferation and induction of apoptosis in glioma cells. It also increased the ratio of the pro-apoptotic protein, Bax, to the anti-apoptotic protein, Bcl-2. Since U87MG has the wild-type p53 gene whereas U251MG harbours a mutated p53 gene, our results indicate that triptolide induces apoptosis in GBM cells via a p53-independent pathway. The dose-dependent inhibition of cell proliferation and induction of apoptosis by triptolide may involve upregulation of Bax and downregulation of Bcl-2.
Introduction
Triptolide, derived from a traditional Chinese herb (Tripterygium wilfordii), has multiple biological effects. Besides its potent immunosuppressive and anti-inflammatory properties, 1,2 it attenuates pulmonary arterial hypertension and neointimal formation in animal models. 3 It also sensitizes cancer cells to tumour necrosis factor-α (TNF-α)-induced apoptosis by inhibiting TNF-α induced activation of nuclear factor κB, which results in the resistance of cancer cells to chemotherapy. 4 When combined with TNF-α, triptolide shows synergistic cytotoxic and apoptotic effects on human cholangiocarcinoma cell lines. 5 In the past few years there has been intensive research on the antineoplastic activity and mechanisms of action of triptolide. It induces apoptosis in many kinds of tumour cell and inhibits the growth and metastasis of tumours, such as prostate cancer, cholangiocarcinoma and multiple myeloma. 6 -10 J Lin, L-Y Chen, Z-X Lin et al.
Effect of triptolide on apoptosis of GBM cells
Glioblastoma multiforme (GBM) is the most common and most malignant type of glioma. 11 It involves multiple genetic and chromosomal abnormalities 12 which cause tumour cells to proliferate uncontrollably and invade aggressively, and there is still a lack of effective therapeutic treatments. In the present study, we investigated the effect of triptolide on the proliferation and apoptosis of GBM cells.
Materials and methods

CELL LINES AND CELL CULTURE
Human glioma cell lines U87MG (wild-type p53 gene) and U251MG (mutant p53 gene) were obtained from the American Type Culture Collection (Manassas, VA, USA) and grown in Dulbecco's modified Eagle medium (DMEM; GIBCO ® , Invitrogen Corp, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS; Life Technologies Inc., Gaithersburg, MD, USA), 100 U/ml penicillin and 100 µg/ml streptomycin in a humidified incubator at 37°C with 95% air and 5% CO 2 . Human fetal astrocytes (HFAs) were isolated from the brains of second-trimester (18 -19 weeks) human fetuses and cultured at a density of 5 × 10 4 cells/cm 2 in F12 medium (GIBCO ® ) plus DMEM (50% + 50%) supplemented with 10% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin. The cells were screened routinely to verify lack of mycoplasma contamination and were used in the log phase of growth.
MTT ASSAY
For the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) colorimetric assay, U87MG and U251MG cells and HFAs were seeded in 96-well culture plates at a density of 2 × 10 4 cells/well in 200 µl culture medium. After 24 h of attachment culture, triptolide (standard preparation; Institute for the Control of Pharmaceutical and Biological Products, Beijing, China) was added at different concentrations (0, 1, 5, 20 and 50 ng/ml) for 20 h in the experimental group and in the control group phosphate buffered saline was added; each was undertaken in triplicate. At the end of incubation, 20 µl of 5 mg/ml MTT (Sigma Aldrich, St Louis, MO, USA) solution was added to each well and samples were incubated for 4 h; 100 µl of 0.01 mol/l HCl -10% sodium dodecyl sulphate (SDS) was then added and optical density was measured at 570 nm by spectrophotometry.
CELL GROWTH CURVE ASSAY
Cells were prepared as for the MTT assay described above. After 24 h of attachment culture, triptolide was added at different concentrations (0, 25 and 50 ng/ml) for 2, 4, 6 or 8 days and numbers of cells were counted by phase contrast microscopy and cell proliferation curves were drawn individually. Each was undertaken in triplicate.
DNA FRAGMENTATION ASSAY
Cells were prepared as for the MTT assay described above. After 24 h of attachment culture, triptolide was added at different concentrations (0, 5, 25 and 100 ng/ml) for 48 h. One to three million cells were harvested in 5 ml lysis buffer (10 mmol/l Tris, pH 7.9, 5 mmol/l EDTA [ethylenediamine tetraacetate], 0.1 mol/l NaCl, 0.5% SDS) with 1 mg/ml pronase and the cells were incubated at 37°C for 2 h. After adding NaCl to a final concentration of 1 mol/l, the cell lysate was kept at 4°C for 24 h and then centrifuged at 57 000 g, at 4°C for 1 h. The supernatant was extracted with phenol and chloroform. The DNA was precipitated by adding 2.5 times the volume of ethanol and was redissolved in TE buffer (10 mmol/l Tris pH 7.9, 1 mmol/l EDTA). Samples of 30 µg of DNA underwent agarose gel electrophoresis.
Triptolide
Cell line
Control a 1 ng/ml 5 ng/ml 20 ng/ml 50 ng/ml HFA 100 ± 11 97 ± 8.7 92 ± 9.7 82.5 ± 9.7* 48.7 ± 5.5** U251MG 100 ± 8.7 94.5 ± 10 80.2 ± 6.7** 54.5 ± 6.7** 5.3 ± 0.7** U87MG 100 ± 8.5 92 ± 9.5 75 ± 7.5** 49.5 ± 4.5** 4.4 ± 0.7** Data are cell survival percentages (mean ± SD) relative to the control. a Treated with complete medium without triptolide. *P < 0.05 and **P < 0.01 versus control group.
TABLE 1: Effect of 24 h triptolide treatment at various doses on glioma cells as measured by the MTT assay
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Cells were prepared and treated with a Ras activation assay. Four days later, protein lysates were prepared with ice-cold RIPA (radioimmunoprecipitation assay) buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS and 1% NP40) supplemented with the proteinase inhibitors aprotinin (1 mg/ml) and phenolmethylsulfonyl fluoride (PMSF, 0.1 mg/ml), and the phosphatase inhibitor sodium orthovanadate (1 mmol/l). Protein concentrations were measured using the Bio-Rad protein assay system (Bio-Rad Laboratories, Richmond, CA, USA).
Extracts containing 30 µg of protein for each sample underwent electrophoresis on 10% SDS-polyacrylamide gel and transferred to 0.45 µm nitrocellulose membranes which were then blocked for 1 h at room temperature in TBST blocking buffer (10 mmol/l Tris-HCl pH 8.0, 150 mM NaCl, 0.1% Tween 20, 5% bovine serum albumin [BSA]), incubated in blocking buffer separately containing 1:1000 diluted anti-Bcl-2, anti-Bax and anti-actin antibody. After extensively washing in TBST blocking buffer, the membranes were incubated for 1 h at room temperature in blocking buffer containing 1:10 000 diluted peroxidase-conjugated anti-rabbit secondary antibody). After washing in TBST, an electrochemiluminescence (ECL) detection system (Life Technologies, Gaithersburg, MD, USA) assay was performed according to the manufacturer's protocol.
STATISTICAL ANALYSIS
Statistical analysis was performed using SPSS ® version 12.0 (SPSS Inc., Chicago, IL, USA). The experimental results are expressed as mean ± SD. One-way analysis of variance and Student's t-test were used to compare differences among groups and P < 0.05 was considered to indicate statistical significance.
Results
INHIBITION OF GLIOMA CELL PROLIFERATION BY TRIPTOLIDE
MTT assay
Triptolide reduced the growth rate of glioma cell lines U87MG and U251MG in a doserelated manner. In both these cell lines, 24 h exposure to triptolide at concentrations of ≥ 5 ng/ml significantly (P < 0.01) decreased the percentage of viable cells. For HFA cells, although ≥ 50 ng/ml triptolide decreased the percentage of viable cells to a P < 0.01 level of significance (Table 1) , only 200 ng/ml triptolide decreased HFA cell viability to levels similar to those for U87MG and U251MG at 50 ng/ml triptolide (data not shown). 
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Growth curve analysis
Analysis of the growth curves of the glioma cell lines U87MG and U251MG showed that triptolide reduced growth rate of both cell lines in a dose-related manner. After 8 days' treatment with 50 ng/ml triptolide, the cell number was only 18.0% and 22.6% of the control value for U87MG (P < 0.01 vs HFAs) ( Fig. 1A) and U251MG cells (P < 0.01 vs HFAs) (Fig. 1B) , respectively. The growthinhibiting effect of triptolide was much weaker in HFAs versus glioma cell lines; 50 ng/ml triptolide for 8 days inhibiting by no more than 35.0% (Fig. 1C ).
EFFECT OF TRIPTOLIDE ON DNA FRAGMENTATION IN GLIOMA CELLS
In both types of glioma cell, the level of genomic DNA fragmentation after 48 h of treatment increased with increasing triptolide concentration. Less fragmentation occurred in HFAs than in glioma cells; the only concentration of triptolide that induced obvious DNA fragmentation in HFAs was 100 ng/ml (Fig. 2 ).
EFFECT OF TRIPTOLIDE ON BAX AND BCL-2
The amount of Bcl-2 protein detected in glioma cells decreased concomitantly with increasing concentrations of triptolide. In particular, the amount of Bcl-2 protein was reduced in both U87MG and U251MG cells exposed to triptolide at 100 ng/ml. This inhibitory effect was not so marked in normal HFAs. Triptolide increased the level of Bax protein in both GBM cells and normal HFAs (Fig. 3 ).
Discussion
The present study shows that triptolide reduces the growth rate of glioma cell lines U87MG and U251MG, as measured by MTT assay and cell growth curve analysis, in a dose-dependent manner. In order to establish whether the growth-inhibitory effect of triptolide was due to the induction of apoptosis, necrosis or simple growth arrest, genomic DNA of the triptolide-treated cells of these cell lines and normal HFAs was extracted and assayed for fragmentation by FIGURE 2: Effect of triptolide on DNA fragmentation in glioma cells as shown by agarose gel electrophoresis. Lanes 1 -4, human fetal astrocytes treated with 0, 5, 25 and 100 ng/ml triptolide, respectively; lanes 5 -8, U87MG cells treated with 0, 5, 25 and 100 ng/ml triptolide, respectively; lanes 9 -12, U251MG cells treated with 0, 5, 25 and 100 ng/ml triptolide, respectively. glioma cells underwent programmed cell death after triptolide treatment. For normal HFAs, a higher concentration of triptolide was required to induce a level of apoptosis similar to that seen in the glioma cells. The results of the proliferation inhibition tests agreed with those of the apoptosis test.
Programmed cell death, or apoptosis, plays an integral role in a variety of biological events, such as morphogenesis, removal of unwanted or harmful cells and tissue homeostasis. Members of the Bcl-2 family have been described as key in the regulation of the apoptotic process. 13 They physically and functionally associate with the mitochondrial membrane, and they include both positive and negative regulators. 14 Interactions between these molecules modulate the apoptotic potential. The activity of Bcl-2 as a potent inhibitor of cell death has been shown not only to lead to the development of cancer, but also to resistance to many anticancer chemotherapeutic agents. 15 On the other hand, Bax, as a pro-apoptotic protein, induces enhanced apoptosis in many types of cancer cell. 16, 17 In the present study, the levels of Bcl-2 protein, determined by Western blot analysis, were reduced by triptolide in both U87MG and U251MG cell lines. In normal HFA cells, however, this inhibitory effect was not so obvious; this may have been a result of the lower level of Bcl-2 in normal cells than in malignant cells. Triptolide increased Bax protein levels in GBM and normal HFA cells.
Since U87MG cells have the wild-type p53 gene while U251MG harbours a mutated p53 gene, our results indicate that triptolide induces apoptosis in GBM cells via a p53independent pathway.
The results of the present study indicate that triptolide inhibits the proliferation of GBM cells and induces apoptosis by upregulation of Bax and downregulation of Bcl-2. The study provides a theoretical basis FIGURE 3: Effect of triptolide on Bax and Bcl-2 protein levels in glioma cells as evaluated by Western blotting. Lanes 1, 4 and 7, HFAs treated with 0, 25 and 100 ng/ml triptolide, respectively; lanes 2, 5 and 8, U251MG cells treated with 0, 25 and 100 ng/ml triptolide, respectively; lanes 3, 6 and 9, U87MG cells treated with 0, 25 and 100 ng/ml triptolide, respectively. 
